The OCR indicative of the extent of mitochondrial OXPHOS, showed a significant increase in KRAS mutation pancreatic cells.[40] Moreover, cells harboring KRAS mutations exhibited heightened susceptibility to OXPHOS inhibitors,[41] instead, KRAS mutations diminished the sensitivity of NSCLC to MEK inhibitors by inducing activation of the OXPHOS.[42] These findings implied that KRAS mutations may promote the progression of NSCLC by enhancing the activity of OXPHOS. This evidence concerns the gene KRAS and non-small cell lung carcinoma.